ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1727

Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

Leah Rooney1, Aine Gorman2, Matthew Turk3, Louise Moore4, Celine O'Brien5, Jared Bierbrier6, Anne Clohessy5, Eamonn Molloy7, Lorraine O Neill8, Fionnuala M. Mc Auliffe5 and Douglas Veale9, 1St Vincent's University Hospital, Dublin, Ireland, 2St Vincents Hospital, Dublin, Ireland, 3St. Vincents University Hospital, Dublin, Ireland, 4Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, 5Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, 6McMaster University, Hamilton, ON, Canada, 7St Vincent's Healthcare Group, Dublin, Ireland, 8St. Vincent's Hospital, Dublin, Ireland, 9University College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2021

Keywords: Behçet's Syndrome, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It presents most commonly during the second and third decades of life, therefore frequently involves women during their reproductive years. The objective of our work was to determine the effect of Behcet’s disease on pregnancy by evaluating the prevalence of fetal and maternal complications through systematic review and meta-analysis.

Methods: We performed a systematic review of the literature using Medline, Web of Science, and the Cochrane library from their inceptions until March 26, 2021. Studies were included if they presented the frequency of complications in cohorts of pregnant patients with a diagnosis of Behcet’s disease. Studies were selected by two independent reviewers and statistics were performed using REVMAN5.4.

Results: 6638 studies were identified of which 16 were included. Among patients’ with Behcet’s disease during pregnancy the prevalence of caesarean section was 23% (CI 10-36% , Figure 1), pre-term birth 11% (CI 8-15%, Figure 2), miscarriage 11% (CI 8-14%), pre-eclampsia 4% (CI 3-6%), intrauterine death 4% (CI 2-7%), new hypertension 6% (2-10%) and 27% of women reported worsening of symptoms related to Behcet’s disease during pregnancy (CI 20-34 , Figure 3).

Conclusion: Approximately one quarter of patients experienced worsening of symptoms related to Behcet’s disease during pregnancy, 1 in 10 had a pre-term delivery and almost 1 in 4 delivered their baby by caesarean section. These results show the importance of close monitoring of patients with Behcet’s disease during pregnancy – both for pregnancy complications and for worsening Behcet’s symptoms.


Disclosures: L. Rooney, None; A. Gorman, None; M. Turk, None; L. Moore, None; C. O'Brien, None; J. Bierbrier, None; A. Clohessy, None; E. Molloy, None; L. O Neill, None; F. Mc Auliffe, None; D. Veale, Abbvie, 1, 5, 6, BMS, 1, 5, Pfizer, 1, 5, 6, Janssen, 1, 5, 6, Eli Lilly, 1, 5, 6, UCB, 1, 5, 6, Novartis, 1, 5, 6, Galapagos/Gilead, 1, 6.

To cite this abstract in AMA style:

Rooney L, Gorman A, Turk M, Moore L, O'Brien C, Bierbrier J, Clohessy A, Molloy E, O Neill L, Mc Auliffe F, Veale D. Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/behcets-disease-a-meta-analysis-of-pregnancy-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-a-meta-analysis-of-pregnancy-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology